<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Five patients with the classical clinical syndrome associated with a deletion of the long arm of chromosome 5, i.e., <z:hpo ids='HP_0001903'>anemia</z:hpo>, <z:mp ids='MP_0000248'>macrocytosis</z:mp>, and <z:hpo ids='HP_0001894'>thrombocytosis</z:hpo>, or a <z:mpath ids='MPATH_458'>normal</z:mpath> platelet count, were treated successfully with subcutaneous low-dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (LDARA-C) </plain></SENT>
<SENT sid="1" pm="."><plain>Prior therapy with other drugs had failed in four of the five patients </plain></SENT>
<SENT sid="2" pm="."><plain>A total of nine complete and one partial hematologic responses were induced in five patients </plain></SENT>
<SENT sid="3" pm="."><plain>Duration of the first hematologic response ranged from 3 to 30+ months </plain></SENT>
<SENT sid="4" pm="."><plain>Two patients (cases 3 and 4) continue in their first hematologic response at 29 and 30 months </plain></SENT>
<SENT sid="5" pm="."><plain>Upon relapse, up to three responses could be reinduced in two patients </plain></SENT>
<SENT sid="6" pm="."><plain>Duration of the subsequent hematologic responses in case 1 was 16, 8, and 10 months and case 2 achieved two responses of 15 and 18+ months duration </plain></SENT>
<SENT sid="7" pm="."><plain>LDARA-C therapy was associated with mild to severe <z:hpo ids='HP_0001875'>neutropenia</z:hpo> and moderate to severe <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Thus, subcutaneous LDARA-C is highly effective in the treatment of patients with <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> associated with deletion of the long-arm of chromosome 5 (5q-) </plain></SENT>
</text></document>